Küng W M, Geyer E, Eppenberger U, Huber P R
Cancer Res. 1980 Nov;40(11):4265-9.
A technique for reproduction and quantitative determination of human cellular retinoic acid-binding protein (CRABP) activity in breast tissue specimens is described. A multiphasic polyacrylamide disc gel electrophoresis system (operative at pH 10.2) was adapted for this purpose. This technique allows, after incubation with tritiated retinoic acid (RA) overnight, the separation of the specific CRABP activity from the nonspecific serum-originated binding activity and from the free RA. Previous purification of the tissue cytosols is therefore not necessary. The same assay method was also used for the determination of the molecular weight (Ferguson plot, m.w. 13,000) and the dissociation constant Kd (2.5 x 10(-7) M) of mammary CRABP. The activity in tissue cytosol, stored at -70 degrees, was found to be stable for at least 3 months. Results from 88 breast tissue specimens of different pathological degree are presented. CRABP activity was found in all tissue categories with progressively increasing amounts from normal tissue to breast cancer. The activity in the cancer tissues (14.85 +/- 12.05 pmol RA bound per mg soluble protein: N = 27) was significantly different (p less than 0.001) from the activity determined in tissue with simple dysplasia without epithelial proliferation [4.3 +/- 2.2 (S.D.) pmol RA bound per mg protein; N = 30]. It is possible that in the cases where high amounts of CRABP activity are found in dysplastic and preneoplastic tissue, a high risk for breast cancer development exists. Therefore, CRABP is tentatively proposed as a dedifferentiation and/or proliferation marker.
本文描述了一种用于在乳腺组织标本中重现和定量测定人细胞视黄酸结合蛋白(CRABP)活性的技术。为此采用了一种多相聚丙烯酰胺圆盘凝胶电泳系统(在pH 10.2下运行)。该技术在与氚标记的视黄酸(RA)孵育过夜后,能够将特异性CRABP活性与非特异性血清来源的结合活性以及游离RA分离。因此无需事先对组织胞质溶胶进行纯化。相同的测定方法还用于确定乳腺CRABP的分子量(弗格森图,分子量13,000)和解离常数Kd(2.5×10⁻⁷ M)。发现在-70℃下储存的组织胞质溶胶中的活性至少3个月保持稳定。给出了88个不同病理程度的乳腺组织标本的结果。在所有组织类别中均发现了CRABP活性,从正常组织到乳腺癌,其含量逐渐增加。癌组织中的活性(每毫克可溶性蛋白结合14.85±12.05 pmol RA:N = 27)与单纯发育异常但无上皮增殖的组织中测定的活性[每毫克蛋白结合4.3±2.2(标准差)pmol RA;N = 30]有显著差异(p < 0.001)。在发育异常和癌前组织中发现大量CRABP活性的情况下,可能存在乳腺癌发生的高风险。因此,初步提出将CRABP作为去分化和/或增殖标志物。